Trial Profile
A Randomised Phase II Trial of Oral Vinorelbine as Second Line Therapy for Patients With Malignant Pleural Mesothelioma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Vinorelbine (Primary)
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- Acronyms VIM
- 04 Oct 2021 Status changed from active, no longer recruiting to completed.
- 08 Jun 2021 Primary endpoint has been met (Progression free survival; defined as the time from randomisation to any progression , according to Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology